Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.

Sci Rep · 2022 · PMC9481868 · PMID 36114233

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A previously reported prospective study on pancreatic cancer showed that the incidence of grade 3–4 hematological adverse events was higher in patients who were heterozygous for UGT1A1 *6 or UGT1A1 *28 than in patients with wild-type UGT1A1 , although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.